Despite the clinical success of cancer immunotherapies including immune checkpoint blockade (ICB) and adoptive cellular therapies (ACTs) across a variety of cancer types, many patients do not respond or ultimately relapse, however, the molecular underpinnings of this are not fully understood. Thus, a systems level understating of the routes to tumor immune evasion is required to inform the design of the next generation of immunotherapy approaches. CRISPR screening approaches have …